CBC Group and CBC Portfolio Company News

Highlights

CBC-backed Jadeite Medicines Announces Exclusive Licensing Agreement with Albireo Pharma to Develop and Promote Odevixibat in Japan

Oct  2021

Jadeite Medicines Inc. (“Jadeite”), a biopharmaceutical company that is backed by Singapore’s CBC Group (“CBC”) and committed to addressing critical unmet medical needs for patients in Japan, today entered into an exclusive licensing agreement with Albireo Pharma, Inc. (Nasdaq: ALBO) for the development and commercialization of odevixibat in Japan for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS) and biliary atresia.

       


CBC-backed Jadeite Medicines Announces Exclusive Licensing Agreement with Albireo Pharma to Develop and Promote Odevixibat in Japan

Oct  2021

Penn mRNA Biology Pioneer Drew Weissman Joins RVAC's Science Advisory Board

Sep  2021

Deal focus: NiKang pursues hard-to-drug targets

Jun  2021

NiKang Therapeutics Announces Completion of $200 Million Series C Financing to Advance Highly Differentiated Small Molecules Addressing Difficult-to-Drug Targets

May  2021

Adcentrx Therapeutics Announces Completion of $50m Series A Financing Led By CBC Group To Accelerate Next-Generation Conjugate Drugs Research & Development

Apr  2021

I-Mab Appoints Leading Immunology and Hematology Experts to Its Scientific Advisory Board

Apr  2021

AbbVie puts $2B on the table for I-Mab cancer collab as biotech nabs $418M raise

Apr  2021

I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium

Apr  2021

I-Mab Added to Nasdaq Biotechnology Index

Apr  2021

AffaMed Therapeutics Announces Merger with EverInsight Therapeutics and Appoints Dayao Zhao, M.D., Ph.D. as CEO

Apr  2021

Nuance Pharma Announces Strategic Licensing Deal with Antibe Therapeutics in China

Apr  2021

Nuance Pharma Closes Series D Financing

Apr  2021

VistaGen Therapeutics and EverInsight Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders in Greater China, South Korea and Southeast Asia

Jun  2020

Everest Medicines Completes US$310 Million Series C Financing

Jun  2020

Hansoh Pharma and NiKang Therapeutics Enter into a Development and Commercialization Partnership for a Novel Treatment for Anti- Viral Diseases in China

Apr  2020

Everest Medicines Announces Approval of Xerava™ from the Health Science Authority in Singapore for the Treatment of Complicated Intra-Abdominal Infections

Apr  2020

Ascletis Receives IND Approval for its HIV Drug ASC09F

Apr  2020

CMAB Biopharma Resumes Full-Scale Operation Following the Coronavirus Disease 2019 (COVID-19) Outbreak

Mar  2020

Clarus Therapeutics Announces Commercial Launch and Availability of JATENZO

Mar  2020

Everest Medicines Appoints Kerry Blanchard, M.D., Ph.D., as Director and Chief Executive Officer

Feb  2020

I-MAB Announces Pricing of U.S. Initial Public Offering

Jan  2020

I-Mab Biopharma Announces Dosing of First Patient in a Pivotal Study of TJ202/MOR202 in Multiple Myeloma in Mainland China

Jan  2020

Everest Medicines Announces Approval of Nefecon’s Clinical Trial Application by the China National Medical Products Administration

Dec  2019

AffaMed Therapeutics Receives NMPA Approval to Initiate Phase III Clinical Trial in China with Herceptin® (Trastuzumab) Biosimilar Candidate AMT901

Dec  2019

CMAB Biopharma and Fapon Biopharma Sign Agreement to Develop and Manufacture a Biologic Oncology Asset

Dec  2019

Everest Medicines Achieved First Patient Dosing Milestone in Etrasimod Phase 3 Clinical Study in Ulcerative Colitis Patients in Asia

Nov  2019

CMAB Biopharma and BJ Bioscience Establish an Exclusive Strategic Partnership

Oct  2019

Everest Medicines Expands Senior Leadership Team

Sep  2019

Calliditas Therapeutics and Everest Medicines Enter into an Agreement to Develop and Commercialize Nefecon for IgA Nephropathy in Greater China and Singapore

Jun  2019

CMAB Biopharma Announces Dr. Wang Yongzhong as CEO to Strengthen Leadership and Continue Business Expansion

May  2019

Everest Medicines Appoints Wende Chen as Chief Commercial Ocer

May  2019

Immunomedics and Everest Medicines Announce Exclusive License Agreement for Sacituzumab Govitecan in East and Southeast Asia Excluding Japan

Apr  2019

Clarus Therapeutics Receives U.S. FDA Approval of JATENZO® (Testosterone Undecanoate Capsules for Oral Use) (CIII) for Testosterone Replacement Therapy in Certain Adult Men

Mar  2019

CMAB Biopharma Secures $34 Million Series B Financing

Apr  2018

info@cbridgecap.com
www.cbridgecap.com
© 2020 CBC Group. All Rights Reserved.